UPSTREAM (EORTC 1559-HNCG)
Research type
Research Study
Full title
A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM"
IRAS ID
236404
Contact name
Anthony KONG
Contact email
Sponsor organisation
European Organisation for Research and Treatment of Cancer
Eudract number
2017-000086-74
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 9 months, 28 days
Research summary
This study is for adults who have head and neck cancer that has spread or recurred after previous treatment. It will use a 'personalised medicine' approach whereby a specific drug is given to patients with specific biomarkers which are genetic abnormalities or clinical characteristics. The purpose of the study is to assess if this personalised medicine approach will be effective and safe for patients with recurrent or metastatic head and neck cancers.
This study will include molecular/genetic testing using fresh tumour biopsy. Based on the results, patients with specific biomarkers will be assigned to a specific group that will use a specific drug that targets the biomarker. Patients will undergo treatment, clinical, laboratory and imaging assessment until the disease progresses. a period of 16 weeks will be used to assess the effect of the drugs. The drugs used in the study are standard chemotherapy, target and immune therapy.
This study will take place in NHS sites in the UK as part of a wider international study. The study is sponsored and coordinated by a non-profit organisation called the EORTC (European Organisation for Research and Treatment of Cancer), based in Brussels.
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
18/WM/0053
Date of REC Opinion
16 Apr 2018
REC opinion
Further Information Favourable Opinion